Skip Nav Destination
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)
Issue Archive
April 15 2008
In this Issue
Table of Contents
INSIDE BLOOD
ASH 50TH ANNIVERSARY REVIEW
PLENARY PAPERS
REVIEW ARTICLES
CHEMOKINES, CYTOKINES, AND INTERLEUKINS
CLINICAL TRIALS AND OBSERVATIONS
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
Clinical Trials & Observations
Kenneth I. Ataga,for the ICA-17043-05 Investigators,Wally R. Smith,for the ICA-17043-05 Investigators,Laura M. De Castro,for the ICA-17043-05 Investigators,Paul Swerdlow,for the ICA-17043-05 Investigators,Yogen Saunthararajah,for the ICA-17043-05 Investigators,Oswaldo Castro,for the ICA-17043-05 Investigators,Elliot Vichinsky,for the ICA-17043-05 Investigators,Abdullah Kutlar,for the ICA-17043-05 Investigators,Eugene P. Orringer,for the ICA-17043-05 Investigators,Greg C. Rigdon,for the ICA-17043-05 Investigators,Jonathan W. Stocker,for the ICA-17043-05 Investigators
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Clinical Trials & Observations
Marco Ladetto,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Federica De Marco,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Fabio Benedetti,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Umberto Vitolo,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Caterina Patti,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Alessandro Rambaldi,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Alessandro Pulsoni,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Maurizio Musso,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Anna M. Liberati,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Attilio Olivieri,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Andrea Gallamini,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Enrico Pogliani,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Delia Rota Scalabrini,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Vincenzo Callea,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Francesco Di Raimondo,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Vincenzo Pavone,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Alessandra Tucci,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Sergio Cortelazzo,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Alessandro Levis,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Mario Boccadoro,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Ignazio Majolino,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Alessandro Pileri,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Alessandro M. Gianni,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Roberto Passera,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Paolo Corradini,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL),Corrado Tarella,for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL)
Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
Clinical Trials & Observations
Elizabeth C. Bluhm,Cécile Ronckers,Robert J. Hayashi,Joseph P. Neglia,Ann C. Mertens,Marilyn Stovall,Anna T. Meadows,Pauline A. Mitby,John A. Whitton,Sue Hammond,Joseph D. Barker,Sarah S. Donaldson,Leslie L. Robison,Peter D. Inskip
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Clinical Trials & Observations
Richard A. Larson,for the IRIS (International Randomized Interferon vs STI571) Study Group,Brian J. Druker,for the IRIS (International Randomized Interferon vs STI571) Study Group,Francois Guilhot,for the IRIS (International Randomized Interferon vs STI571) Study Group,Stephen G. O'Brien,for the IRIS (International Randomized Interferon vs STI571) Study Group,Gilles J. Riviere,for the IRIS (International Randomized Interferon vs STI571) Study Group,Tillmann Krahnke,for the IRIS (International Randomized Interferon vs STI571) Study Group,Insa Gathmann,for the IRIS (International Randomized Interferon vs STI571) Study Group,Yanfeng Wang,for the IRIS (International Randomized Interferon vs STI571) Study Group
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium
Clinical Trials & Observations
Karin Ekström Smedby,Claire M. Vajdic,Michael Falster,Eric A. Engels,Otoniel Martínez-Maza,Jennifer Turner,Henrik Hjalgrim,Paolo Vineis,Adele Seniori Costantini,Paige M. Bracci,Elizabeth A. Holly,Eleanor Willett,John J. Spinelli,Carlo La Vecchia,Tongzhang Zheng,Nikolaus Becker,Silvia De Sanjosé,Brian C.-H. Chiu,Luigino Dal Maso,Pierluigi Cocco,Marc Maynadié,Lenka Foretova,Anthony Staines,Paul Brennan,Scott Davis,Richard Severson,James R. Cerhan,Elizabeth C. Breen,Brenda Birmann,Andrew E. Grulich,Wendy Cozen
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Clinical Trials & Observations
Heinz Ludwig,Brian G. M. Durie,Vanessa Bolejack,Ingemar Turesson,Robert A. Kyle,Joan Blade,Rafael Fonseca,Meletios Dimopoulos,Kazuyuki Shimizu,Jesus San Miguel,Jan Westin,Jean-Luc Harousseau,Meral Beksac,Mario Boccadoro,Antonio Palumbo,Bart Barlogie,Chaim Shustik,Michele Cavo,Philip R. Greipp,Douglas Joshua,Michel Attal,Pieter Sonneveld,John Crowley
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)
Clinical Trials & Observations
John A. Thompson,Richard I. Fisher,Michael LeBlanc,Stephen J. Forman,Oliver W. Press,Joseph M. Unger,Auayporn P. Nademanee,Patrick J. Stiff,Stephen H. Petersdorf,Alexander Fefer
HEMATOPOIESIS AND STEM CELLS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes
Marc Tjwa,Lola Bellido-Martin,Yuan Lin,Esther Lutgens,Stéphane Plaisance,Françoise Bono,Nathalie Delesque-Touchard,Caroline Hervé,Rute Moura,An D. Billiau,Cristina Aparicio,Marcel Levi,Mat Daemen,Mieke Dewerchin,Florea Lupu,Jef Arnout,Jean-Marc Herbert,Mark Waer,Pablo García de Frutos,Björn Dahlbäck,Peter Carmeliet,Marc F. Hoylaerts,Lieve Moons
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell,Tarif Awad,Julie A. Johnson,Brian F. Gage,Mat Falkowski,Paul Gardina,Jason Hubbard,Yaron Turpaz,Taimour Y. Langaee,Charles Eby,Cristi R. King,Amy Brower,John R. Schmelzer,Ingrid Glurich,Humberto J. Vidaillet,Steven H. Yale,Kai Qi Zhang,Richard L. Berg,James K. Burmester
IMMUNOBIOLOGY
Colocalization of the IL-12 receptor and FcγRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-γ
Sri Vidya Kondadasula,Julie M. Roda,Robin Parihar,Jianhua Yu,Amy Lehman,Michael A. Caligiuri,Susheela Tridandapani,Richard W. Burry,William E. Carson, III
Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection
Katherine K. Wynn,Zara Fulton,Leanne Cooper,Sharon L. Silins,Stephanie Gras,Julia K. Archbold,Fleur E. Tynan,John J. Miles,James McCluskey,Scott R. Burrows,Jamie Rossjohn,Rajiv Khanna
NEOPLASIA
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis
Brian V. Balgobind,Pieter Van Vlierberghe,Ans M. W. van den Ouweland,H. Berna Beverloo,Joan N. R. Terlouw-Kromosoeto,Elisabeth R. van Wering,Dirk Reinhardt,Martin Horstmann,Gertjan J. L. Kaspers,Rob Pieters,C. Michel Zwaan,Marry M. Van den Heuvel-Eibrink,Jules P. P. Meijerink
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
Sanne Lugthart,Ellen van Drunen,Yvette van Norden,Antoinette van Hoven,Claudia A. J. Erpelinck,Peter J. M. Valk,H. Berna Beverloo,Bob Löwenberg,Ruud Delwel
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Artur Gontarewicz,Stefan Balabanov,Gunhild Keller,Riccardo Colombo,Alessio Graziano,Enrico Pesenti,Daniel Benten,Carsten Bokemeyer,Walter Fiedler,Jürgen Moll,Tim H. Brümmendorf
RED CELLS
TRANSPLANTATION
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique
Stephan Mielke,Raquel Nunes,Katayoun Rezvani,Vicki S. Fellowes,Annie Venne,Scott R. Solomon,Yong Fan,Emma Gostick,David A. Price,Christian Scotto,Elizabeth J. Read,A. John Barrett
CORRESPONDENCE
ERRATUM
-
Cover Image
Cover Image
Merged topographic fluorescence near-field scanning optical microscopy images of αβ TCR on Vβ5+ T cells. See the related article by Chen et al, beginning on page 4220.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals